Assenagon Asset Management S.A. Has $21.58 Million Stock Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Assenagon Asset Management S.A. boosted its position in shares of Cryoport, Inc. (NASDAQ:CYRX) by 487.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,393,156 shares of the company’s stock after buying an additional 1,156,106 shares during the quarter. Assenagon Asset Management S.A. owned approximately 2.85% of Cryoport worth $21,580,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CYRX. Tower Research Capital LLC TRC lifted its stake in shares of Cryoport by 228.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the company’s stock valued at $36,000 after purchasing an additional 1,433 shares during the period. Quarry LP acquired a new position in shares of Cryoport in the 2nd quarter valued at $40,000. Captrust Financial Advisors lifted its stake in shares of Cryoport by 308.3% in the 2nd quarter. Captrust Financial Advisors now owns 2,319 shares of the company’s stock valued at $72,000 after purchasing an additional 1,751 shares during the period. FMR LLC lifted its stake in shares of Cryoport by 34.1% in the 1st quarter. FMR LLC now owns 2,935 shares of the company’s stock valued at $70,000 after purchasing an additional 747 shares during the period. Finally, State of Wyoming lifted its stake in shares of Cryoport by 42.7% in the 4th quarter. State of Wyoming now owns 3,026 shares of the company’s stock valued at $53,000 after purchasing an additional 905 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Price Performance

CYRX stock opened at $18.12 on Thursday. The stock has a 50-day moving average price of $15.95 and a two-hundred day moving average price of $14.37. The stock has a market cap of $887.52 million, a PE ratio of -8.24 and a beta of 1.61. The company has a current ratio of 11.73, a quick ratio of 11.16 and a debt-to-equity ratio of 0.82. Cryoport, Inc. has a 1 year low of $9.00 and a 1 year high of $24.30.

Analyst Ratings Changes

Several analysts recently commented on the company. UBS Group raised their price objective on Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a research note on Friday, March 15th. Stephens reaffirmed an “equal weight” rating and set a $17.00 price objective on shares of Cryoport in a research note on Wednesday, March 13th. Finally, Needham & Company LLC dropped their price objective on Cryoport from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, March 13th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, Cryoport presently has a consensus rating of “Hold” and a consensus target price of $18.29.

Insiders Place Their Bets

In other Cryoport news, CEO Jerrell Shelton sold 2,631 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $17.54, for a total transaction of $46,147.74. Following the completion of the transaction, the chief executive officer now owns 692,182 shares in the company, valued at approximately $12,140,872.28. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CEO Jerrell Shelton sold 2,631 shares of Cryoport stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $17.54, for a total value of $46,147.74. Following the sale, the chief executive officer now owns 692,182 shares of the company’s stock, valued at $12,140,872.28. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ramkumar Mandalam sold 3,217 shares of Cryoport stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $14.68, for a total value of $47,225.56. Following the completion of the sale, the director now directly owns 43,187 shares in the company, valued at approximately $633,985.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 73,940 shares of company stock worth $1,147,538. Corporate insiders own 10.50% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.